A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
12/10/2021at 07:35

Lundbeck CEO expects foundation backing for large acquisitions

If Lundbeck is to stimulate growth, a large-scale acquisition may be one option, the CEO says, though she acknowledges risk must be considered.
Deborah Dunsire, CEO at Lundbeck | Photo: Gregers Tycho/ERH
by torben salomonsen, translated by catherine brett

Long-term goals are more important than short-term solutions at Lundbeck. After speaking with the CEO, Danish financial daily Børsen reports that if the company wants to grow, a larger acquisition would be a clear option, but in Lundbeck's case, risk is a big concern for the foundation that owns the firm.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Lundbeck's interest in the Indian market has suffered a blow, but the company doesn't want to say why it is suddenly ceasing operations completely. | Photo: Foto af Ulrich Quistgaard

    Lundbeck silent on shutdown of Indian operations

    For subscribers

  • Photo: Gregers Tycho/Ritzau/Ritzau Scanpix

    Lundbeck CEO joins board of directors at Syros Pharmaceuticals

    For subscribers

  • Photo: Jens Dresling

    Lundbeck wins patent case against six generic medicine producers

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

Multiple sclerosis treatment Kesimpta, based on Genmab-developed ofatumumab, has generated more than analysts predicted in Q4’22.
  • Janssen's books disappointing sales of Genmab-developed Darzalex
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Foto: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Foto: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk meets upgraded guidance, setting new revenue record

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

Novo Nordisk doubles obesity sales in 2022

For subscribers

Further reading

Anders Hinsby (left), Thomas Kirkegaard Jensen, and Anders Vadsholt | Foto: Anne Bæk/Ritzau Scanpix
Pharma & biotech

Orphazyme trio founds new firm focused on neurology and rare diseases

Anders Hinsby, Anders Vadsholt, and Thomas Kirkegaard Jensen – all three key figures from now-defunct biotech company Orphazyme – have established a new company using experiences from the past.

For subscribers

Foto: Novo Nordisk / PR
Pharma & biotech

Novo Nordisk wins case in US appeals court

Three pharmaceutical firms, including Novo Nordisk, have won a case in a US appeals court, which agreed that the drugmakers can limit deliveries of federally discounted drugs.

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk predicts wide range for 2023 sales growth

The Danish drugmaker has released its 2023 guidance with a sales growth expectation of 13–19%. (Updated)

For subscribers

Latest news

  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, setting new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Maersk and German start-up wants to enhance emission visibility for global e-trade – 08:27
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
  • Pfizer hopes Covid-19 sales will increase in the long run – 31 Jan
  • Amgen takes on Abbvie blockbuster Humira with unusual price plan – 31 Jan
See all

Jobs

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Senior Regulatory Affairs Professional

  • Commercial Director

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Experienced Patent Counsel

  • Head of Regulatory Affairs Danmark

  • Clinical Operational Associate

  • Lead Data Architect

  • Application Manager

  • Regulatory Affairs Professional

See all jobs

Jobs

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Senior Regulatory Affairs Professional

  • Commercial Director

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Experienced Patent Counsel

  • Head of Regulatory Affairs Danmark

  • Clinical Operational Associate

  • Lead Data Architect

  • Application Manager

  • Regulatory Affairs Professional

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge